
## Weiping Yu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12084258/publications.pdf Version: 2024-02-01



WEIDING YU

#	Article	IF	CITATIONS
1	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology, 2012, 8, 114-126.	9.6	832
2	Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2013, 39, 306-318.	4.3	813
3	Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients. Schizophrenia Bulletin, 2013, 39, 295-305.	4.3	259
4	Body Weight and Metabolic Adverse Effects of Asenapine, lloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. CNS Drugs, 2012, 26, 733-759.	5.9	136
5	CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 186-192.	1.4	30
6	Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophrenia Research, 2013, 143, 358-362.	2.0	21
7	Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study. PLoS ONE, 2019. 14. e0210674.	2.5	2